Resubmit the supplemental New Drug Application for pimavanserin
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 21 Dec 2021
- Due
- 31 Mar 2022
- Delivered
- February 2022
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Resubmission of the sNDA to the U.S. Food and Drug Administration (FDA) is planned for the first quarter of 2022.”
What we found
Evidence strength A What the grades mean
The company successfully resubmitted the supplemental New Drug Application for pimavanserin to the FDA in February 2022, which is within the first quarter of 2022 deadline.
-
A Acadia Pharmaceuticals Inc. 10-Q filed 2022-08-09
“In February 2022, we submitted to the FDA an sNDA for NUPLAZID for the treatment of hallucinations and delusions associated with ADP.” ✓ confirmed on the page
Market reaction: the shares moved -7.0% against the S&P 500 over the three sessions around the disclosure (8 Aug 2022 to 11 Aug 2022). What this measures
Checked 1 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Regulatory submission
- Indicative materiality
- High rules
- Action
- Resubmit
- Deliverable
- sNDA for pimavanserin
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Acadia Pharmaceuticals Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-ACAD-002574 · Corrections policy